Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)

Inclusion Criteria: 1. Age 19 and more; and 2. Subjects who scheduled for percutaneous coronary intervention(PCI) with Firehawk® drug-eluting stent 3. At least one of the following high-risk factors; * Clinical factors: diabetes, chronic kidney disease (GFR \< 60ml/min/1.73m2), LV dysfunction (LV EF \< 45%), or troponin (+). * Lesion- or procedure-related factors: left main PCI, chronic total occlusion, bifurcation lesion requiring two-stent technique, severe calcification, in-stent restenosis, multi-vessel PCI (≥ 2 vessels requiring stent implantation), PCI for ≥ 3 lesions, ≥ 3 stents implanted, or total stent length \> 60 mm. * High platelet reactivity: VerifyNow PRU ≥ 266. Exclusion Criteria: 1. Cardiogenic shock at the index admission 2. Bleeding tendency, congenital or acquired 3. Active bleeding or high-risk for major bleeding (e.g. active peptic ulcer disease, gastrointestinal pathology with a high-risk for bleeding, malignancies with a high-risk for bleeding) 4. Need for chronic oral anticoagulation 5. History of intracranial hemorrhage 6. Intracranial neoplasm, AV fistula or aneurysm 7. Platelet counts \< 100,000/mm3 8. Liver cirrhosis with ascites or coagulopathy 9. Dialysis-impending or -dependent renal failure 10. Pregnant and/or lactating women 11. Increased risk of bradycardia events (sick sinus, AV block grade II or III, bradycardia-induced syncope) 12. Concomitant oral or i.v. therapy with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice \>1L/day), CYP3A substrates with narrow therapeutic indices (e.g., cyclosporine, quinidine), or strong CYP3A inducers (e.g., rifampin/ rifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital) that cannot be safely discontinued 13. Concurrent medical condition with a life expectancy of less than 1 years